Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial
- DOI
- 10.1007/s44402-026-00064-w
- Published
- 2026-04-08
- Container
- Ophthalmic and Physiological Optics
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s44402-026-00064-w,
title = {Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01\% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial},
author = {Karla Zadnik and Erica Schulman and Ian Flitcroft and Jennifer S. Fogt and Louis C. Blumenfeld and Tung M. Fong and Eric Lang and Simon P. Chandler and Houman D. Hemmati and Unknown},
year = {2026},
journal = {Ophthalmic and Physiological Optics},
doi = {10.1007/s44402-026-00064-w},
url = {https://doi.org/10.1007/s44402-026-00064-w}
}RIS
TY - JOUR TI - Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial AU - Karla Zadnik AU - Erica Schulman AU - Ian Flitcroft AU - Jennifer S. Fogt AU - Louis C. Blumenfeld AU - Tung M. Fong AU - Eric Lang AU - Simon P. Chandler AU - Houman D. Hemmati AU - Unknown PY - 2026 JO - Ophthalmic and Physiological Optics DO - 10.1007/s44402-026-00064-w UR - https://doi.org/10.1007/s44402-026-00064-w ER -
APA
Zadnik, K., Schulman, E., Flitcroft, I., Fogt, J. S., Blumenfeld, L. C., Fong, T. M., Lang, E., Chandler, S. P., Hemmati, H. D., & Unknown (2026). Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial. Ophthalmic and Physiological Optics. https://doi.org/10.1007/s44402-026-00064-w
Source records
- crossref · retrieved 2026-11-10T12:13:57.560Z